Hidradenitis suppurativa clinical trials

Explore recruiting hidradenitis suppurativa clinical trials.

Recruiting hidradenitis suppurativa studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hidradenitis suppurativa trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Germany, Ireland, Greece, Bulgaria, Spain, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa

Poland, Hungary, Netherlands, Germany, Czechia, Spain +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa

Hungary, Spain, France, Belgium, Sweden, Germany +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Belgium, Germany, Austria, Poland, Spain, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Slovakia, Italy, Hungary, Portugal, Germany, Finland +12 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderate to Severe Hidradenitis Suppurativa

Spain, France, Netherlands, Germany, Italy

Phase II and Phase III (Integrated) EU CTIS Study details

Hidradenitis suppurativa trials by city

Hidradenitis suppurativa clinical trials

Recruiting hidradenitis suppurativa studies right now

A Study of LAD191 in Adults With Hidradenitis Suppurativa

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

SAR447971 First-in-human Study

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Also recruiting in Europe

A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa

A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderate to Severe Hidradenitis Suppurativa

Hidradenitis suppurativa trials by city

Other conditions